+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ewing Sarcoma - Pipeline Review, H1 2020

  • ID: 5117074
  • Drug Pipelines
  • May 2020
  • Region: Global
  • 701 pages
  • Global Markets Direct

FEATURED COMPANIES

  • A2A Pharmaceuticals Inc
  • Aurora BioPharma Inc
  • ENB Therapeutics LLC
  • Incyte Corp
  • NantKwest Inc
  • Pharma Mar SA
  • MORE
Ewing Sarcoma - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma – Pipeline Review, H1 2020, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.

Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 21, 13, 1, 25 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 3 and 1 molecules, respectively.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • A2A Pharmaceuticals Inc
  • Aurora BioPharma Inc
  • ENB Therapeutics LLC
  • Incyte Corp
  • NantKwest Inc
  • Pharma Mar SA
  • MORE
  • Introduction
  • Ewing Sarcoma - Overview
  • Ewing Sarcoma - Therapeutics Development
  • Ewing Sarcoma - Therapeutics Assessment
  • Ewing Sarcoma - Companies Involved in Therapeutics Development
  • Ewing Sarcoma - Drug Profiles
  • Ewing Sarcoma - Dormant Projects
  • Ewing Sarcoma - Discontinued Products
  • Ewing Sarcoma - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Ewing Sarcoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Ewing Sarcoma - Pipeline by A2A Pharmaceuticals Inc, H1 2020
  • Ewing Sarcoma - Pipeline by Aadi Bioscience Inc, H1 2020
  • Ewing Sarcoma - Pipeline by Advenchen Laboratories LLC, H1 2020
  • Ewing Sarcoma - Pipeline by Altay Therapeutics Inc, H1 2020
  • Ewing Sarcoma - Pipeline by Amgen Inc, H1 2020
  • Ewing Sarcoma - Dormant Projects, H1 2020
  • Ewing Sarcoma - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Ewing Sarcoma - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Ewing Sarcoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
  • A2A Pharmaceuticals Inc
  • Aadi Bioscience Inc
  • Advenchen Laboratories LLC
  • Altay Therapeutics Inc
  • Amgen Inc
  • AntiCancer Inc
  • APEIRON Biologics AG
  • Atlanthera
  • Aurora BioPharma Inc
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Cebiotex SL
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Eisai Co Ltd
  • ENB Therapeutics LLC
  • EntreChem SL
  • Exelixis Inc
  • Gibson Oncology LLC
  • GlaxoSmithKline Plc
  • Gradalis Inc
  • ImmunityBio Inc
  • Incyte Corp
  • Instituto Ortopedico Rizzoli
  • Ipsen SA
  • JSK Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • MacroGenics Inc
  • Mana Therapeutics Inc
  • MediaPharma SRL
  • Merck & Co Inc
  • Nanovalent Pharmaceuticals Inc
  • NantKwest Inc
  • Natsar Pharmaceuticals Inc
  • Novartis AG
  • Ohara Pharmaceutical Co Ltd
  • Oncoceutics Inc
  • Oncology Pharma Inc
  • Oncomatryx Biopharma SL
  • Oncternal Therapeutics
  • Pfizer Inc
  • Pharma Mar SA
  • Provectus Biopharmaceuticals Inc
  • Salarius Pharmaceuticals Inc
  • Shionogi & Co Ltd
  • Sorrento Therapeutics Inc
  • Syros Pharmaceuticals Inc
  • Tarveda Therapeutics Inc
  • TheraPten Biosciences Inc
  • Tyme Technologies Inc
Note: Product cover images may vary from those shown
Adroll
adroll